Sanofi background on key drugs, stock seen through long term lens

Sanofi faces a long term reshaping of its portfolio after setbacks around multiple sclerosis drug tolebrutinib and the Lantus insulin era, while Dupixent continues to anchor growth and investors track the Paris listing.

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 13:51.

Sanofi S.A. (FR0000127771) remains one of the largest European pharma names on Euronext Paris, with a market cap well above 100 billion euros and a diversified prescription portfolio. The stock is frequently compared with peers such as Novartis and Pfizer in global healthcare indices.

What Reuters and filings show

In mid 2022 Sanofi announced it would halt worldwide clinical trials of its experimental multiple sclerosis drug tolebrutinib after liver safety signals, a move documented in company statements and industry coverage. A Reuters report from July 2022 describes the tolebrutinib trial suspension and notes the importance of neurology for Sanofi's pipeline.

The decision to halt those studies forced Sanofi to reassess parts of its research portfolio and sharpen focus on areas with clearer risk profiles, such as immunology and oncology. Company filings and investor presentations show capital being reallocated to projects with stronger safety and efficacy data in Phase II and III stages.

Analyst views on Dupixent and beyond

Several analyst houses see the asthma and eczema drug Dupixent as Sanofi's main growth driver, with blockbuster status and expanding indications in respiratory and dermatological diseases. Morningstar analysis on Sanofi highlights Dupixent's role in long term revenue mix and sets medium term expectations for margin resilience.

Other market commentary emphasizes Sanofi's broader specialty care franchise, including rare disease treatments and vaccines, as key to defending its position against competitors such as GSK and Johnson & Johnson. Analysts also watch how management balances shareholder returns via dividends with ongoing investment in high risk, high reward research projects.

How Sanofi makes its money

Sanofi's core business model rests on discovering, developing and commercializing prescription drugs and vaccines that address chronic and acute diseases in large patient populations. Revenue is driven largely by specialty care medicines in areas such as immunology, oncology and rare diseases.

Where the stock trades today

Sanofi S.A. shares trade on Euronext Paris under the ticker SAN, quoted in euros as of the latest available market data.

Sanofi S.A. at a glance

• Company: Sanofi S.A.
• ISIN: FR0000127771
• WKN: 920657
• Ticker: SAN
• Trading venue: Euronext Paris
• Price (as of 2026-06-27, 11:45): 95.00 EUR
• Market cap: 120000000000 EUR (as of 2026-06-27)
• Sector / industry: Health Care - Pharmaceuticals
• Index membership: CAC 40
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.